119.68 +0.15 (0.13%)
After hours: 4:11PM EST
|Bid||118.00 x 900|
|Ask||119.83 x 900|
|Day's Range||118.50 - 121.21|
|52 Week Range||105.12 - 179.65|
|Beta (3Y Monthly)||3.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||173.17|
CORAL GABLES, FL / ACCESSWIRE / December 13, 2018 / Big marijuana stock news is circulating once again on Thursday. Late Wednesday afternoon the next phase of the Farm Bill moved forward. The House of ...
This marijuana stock's performance over the next few years will likely heavily hinge upon sales of the newly launched epilepsy drug Epidiolex.
HENDERSON, NV / ACCESSWIRE / December 12, 2018 / Here are some of the best ways to play the cannabis market. Today we are highlighting: CleanSpark, Inc. (CLSK), Canopy Growth Corporation (NYSE: CGC), GW ...
HENDERSON NV / ACCESSWIRE / December 12, 2018 / Cannabis indoor grow operations accounts for 1% of electricity consumption in the US. Here are a few companies you should look at to capitalize on this fact. ...
/ The marijuana industry and marijuana stocks for that matter have been getting a lot of attention lately and it has begun to translate into new job growth. According to a new report from Vangst, a recruitment and job placement agency focused on the cannabis industry, these are some of the most popular jobs right now are legal cannabis cultivation and retail sales management. In addition to this, the cannabis industry is projected to grow by 220% in 2019 alone, according to the report.
With the stock market under pressure, not many investors are flocking to speculative holdings like Canopy Growth (NYSE:CGC). Specifically, Canada’s decision to legalize recreational marijuana use in mid-October caused a temporary spike, which was eventually sold into as the overall market came under pressure. Is Canopy Growth Stock a Good Company?
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $127.05, marking a +0.63% move from the previous day.
Bank of America Merrill Lynch doubled down on its bullish thesis for GW Pharmaceuticals plc (NASDAQ: GWPH ) and its flagship Epidiolex drug after attending the American Epilepsy Society's annual meeting. ...
Furthermore, the latest break that US legislation has given marijuana legalization has aided in the benefit a many a pot stock this month. Leafbuyer Technologies Inc. (LBUY) has been on a growth path for the better part of the year. Leafbuyer (LBUY) has built its business to be a trusted online resource for finding legal marijuana deals and specials.
Less than a week after its most recent update on GW Pharmaceuticals plc (NASDAQ: GWPH ), Cantor Fitzgerald lowered its price target for the stock Monday after the issuance of the company's 10-K report. ...
GW Pharmaceuticals’ stock is suffering, even though the biopharmaceutical company has great potential.
CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / This year has been pivotal for marijuana stocks . Not only did the entire country of Canada legalize recreational marijuana but new states in the US have ...
Though still exceptionally strict with recreational pot use, this country will now allow hemp-based cannabidiol products to be prescribed to select patients.
CV Sciences, somewhat incredibly, has risen by a factor of 21x in just the last year. CVSI stock, in fact, has risen more than 1,000% just since April. Unlike a number of OTC marijuana-related stocks, CV Sciences has a real business.
Williams isn’t growing marijuana but hemp, a kind of cannabis plant that offers the medicinal benefits of pot without the high. Like a growing number of struggling U.S. farmers, Williams is betting on hemp as an entirely new cash crop. Lumped in with its intoxicating cousin for decades under federal laws restricting controlled substances, Congress is on the verge of fully legalizing hemp under a new farm-bill agreement struck Thursday.
GW Pharmaceuticals narrowly lagged Wall Street's fiscal fourth-quarter sales views late Tuesday, prompting GW stock to slide in extended action.
GW Pharmaceuticals plc (NASDAQ: GWPH ) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view. The Analyst ...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 27) ...